Logo image of KMTS

KESTRA MEDICAL TECHNOLOGIES (KMTS) Stock Fundamental Analysis

NASDAQ:KMTS - Nasdaq - BMG524411052 - Common Stock - Currency: USD

19.63  -1.05 (-5.08%)

After market: 19.63 0 (0%)

Fundamental Rating

2

Overall KMTS gets a fundamental rating of 2 out of 10. We evaluated KMTS against 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of KMTS have multiple concerns. While showing a medium growth rate, KMTS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KMTS had negative earnings in the past year.
KMTS had a negative operating cash flow in the past year.
KMTS Yearly Net Income VS EBIT VS OCF VS FCFKMTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

KMTS has a Return On Assets of -76.86%. This is in the lower half of the industry: KMTS underperforms 75.53% of its industry peers.
KMTS's Return On Equity of -332.14% is on the low side compared to the rest of the industry. KMTS is outperformed by 81.38% of its industry peers.
Industry RankSector Rank
ROA -76.86%
ROE -332.14%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KMTS Yearly ROA, ROE, ROICKMTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2023 2024 0 -1K -2K -3K

1.3 Margins

With a Gross Margin value of 26.86%, KMTS is not doing good in the industry: 77.66% of the companies in the same industry are doing better.
KMTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KMTS Yearly Profit, Operating, Gross MarginsKMTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

KMTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KMTS has been increased compared to 1 year ago.
Compared to 1 year ago, KMTS has an improved debt to assets ratio.
KMTS Yearly Shares OutstandingKMTS Yearly Shares OutstandingYearly Shares Outstanding 2021 2023 2024 10M 20M 30M 40M
KMTS Yearly Total Debt VS Total AssetsKMTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of 0.45, we must say that KMTS is in the distress zone and has some risk of bankruptcy.
KMTS has a Altman-Z score (0.45) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.54 is on the high side and indicates that KMTS has dependencies on debt financing.
The Debt to Equity ratio of KMTS (1.54) is worse than 82.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Altman-Z 0.45
ROIC/WACCN/A
WACC9.02%
KMTS Yearly LT Debt VS Equity VS FCFKMTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2023 2024 0 20M -20M 40M -40M -60M -80M

2.3 Liquidity

KMTS has a Current Ratio of 2.84. This indicates that KMTS is financially healthy and has no problem in meeting its short term obligations.
KMTS has a Current ratio (2.84) which is in line with its industry peers.
KMTS has a Quick Ratio of 2.84. This indicates that KMTS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.84, KMTS is in the better half of the industry, outperforming 61.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.84
Quick Ratio 2.84
KMTS Yearly Current Assets VS Current LiabilitesKMTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for KMTS have decreased strongly by -15.36% in the last year.
Looking at the last year, KMTS shows a very strong growth in Revenue. The Revenue has grown by 264.53%.
EPS 1Y (TTM)-15.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)264.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 9.14% on average over the next years. This is quite good.
The Revenue is expected to grow by 66.96% on average over the next years. This is a very strong growth
EPS Next Y0.19%
EPS Next 2Y3.16%
EPS Next 3Y9.14%
EPS Next 5YN/A
Revenue Next Year113.57%
Revenue Next 2Y74.43%
Revenue Next 3Y66.96%
Revenue Next 5YN/A

3.3 Evolution

KMTS Yearly Revenue VS EstimatesKMTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
KMTS Yearly EPS VS EstimatesKMTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KMTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KMTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KMTS Price Earnings VS Forward Price EarningsKMTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KMTS Per share dataKMTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.16%
EPS Next 3Y9.14%

More info and screens

0

5. Dividend

5.1 Amount

KMTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KESTRA MEDICAL TECHNOLOGIES

NASDAQ:KMTS (6/3/2025, 4:30:02 PM)

After market: 19.63 0 (0%)

19.63

-1.05 (-5.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-14 2025-04-14/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.01B
Analysts85
Price Target28.05 (42.89%)
Short Float %4.59%
Short Ratio5.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22
P/FCF N/A
P/OCF N/A
P/B 37.33
P/tB 37.33
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0.89
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.86%
ROE -332.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.86%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.4%
Cap/Sales 43.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.84
Quick Ratio 2.84
Altman-Z 0.45
F-ScoreN/A
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y0.19%
EPS Next 2Y3.16%
EPS Next 3Y9.14%
EPS Next 5YN/A
Revenue 1Y (TTM)264.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year113.57%
Revenue Next 2Y74.43%
Revenue Next 3Y66.96%
Revenue Next 5YN/A
EBIT growth 1Y-5.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.97%
EBIT Next 3Y14.56%
EBIT Next 5YN/A
FCF growth 1Y-0.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.39%
OCF growth 3YN/A
OCF growth 5YN/A